580 Recruiting Trials

Clinical Trials
for Cancer in Virginia

580 clinical trials for Cancer are currently recruiting participants at study sites in Virginia. Study-related care is provided at no cost.

580
Recruiting trials
393
Study sites
48
Cities
392
Industry-sponsored
242
Phase 2
180
Phase 3

Cancer clinical trials in Virginia: what to expect

Cancer is the single largest area of clinical research, and nearly every recruiting cancer trial is written for one cancer type at one stage. Most test a new drug or combination against the current standard treatment: targeted medicines matched to a mutation found in the tumor, immunotherapies that help the immune system recognize cancer cells, antibody-drug conjugates and cell therapies. Others study surgery and radiation techniques, ways to reduce side effects, and screening or prevention in people at higher risk.

In Virginia, recruiting cancer studies are concentrated in Fairfax, Richmond, Charlottesville and Norfolk, with sites in 44 other cities. 392 of the 580 are run by a drug or device company, which usually means a larger study with travel reimbursement; the rest are academic or hospital-led.

Who cancer trials usually look for

Every listing names the cancer type and stage it enrolls, and most also state how many earlier treatments you may have had: some are for people newly diagnosed, many are for cancer that has come back or spread after a first treatment stopped working. Targeted-therapy trials require a specific result on tumor testing, which the site can arrange if it has not been done. Trials generally ask that you are well enough for daily activity (a "performance status" the doctor scores), that blood counts and liver and kidney function are adequate, and that a few weeks have passed since your last treatment.

Having advanced or metastatic cancer does not rule you out. A large share of recruiting trials are designed specifically for it.

What taking part involves

Screening reviews your pathology and scans, often with new blood work and sometimes a fresh biopsy. Treatment then follows a cycle, typically every two or three weeks, with scans every six to twelve weeks to measure the response. Early-phase trials have more frequent visits at the start. The study drug and study-specific tests are provided at no cost; standard care that you would receive anyway is usually billed to insurance as normal. A placebo on its own is rare in cancer trials: when there is one, it is added to the standard treatment, and the consent form says so.

Questions worth asking the study team

Whether the trial is randomized and what the comparison treatment is; what happens if the cancer grows during the study; whether you can keep receiving the drug afterward if it is working; how the trial fits with the plan your own oncologist has suggested; and what travel or lodging support is offered. Your oncologist can also refer you directly.

Showing 20 of 580 recruiting Cancer trials in Virginia

Pan Tumor Rollover Study
PHASE2 Huntsville, Alabama +4 sites NCT03899155
This trial is looking for patients with cancer who have had a good response to previous treatments. Participants will continue receiving nivolumab alone or in combination with other cancer therapies to study long-term safety.
Recruiting
A Study of OR502, a Monoclonal Antibody Targeting LILRB2, Alone and in Combination With Anticancer Agents
PHASE1 Fairfax, Virginia +3 sites NCT06090266
This trial is looking for adults with advanced solid tumors, like lung cancer or melanoma. Participants will receive a treatment called OR502 alone or with another cancer treatment to see how well it works and what side effects it has.
Recruiting
A Study in Patients With Advanced Cancers
PHASE1 Fairfax, Virginia +2 sites NCT05320588
This trial is looking for patients with advanced cancers who have tried standard treatments without success. Participants will receive the study drug BIO-106, either alone or with another treatment called pembrolizumab.
Recruiting
The ECOG-ACRIN SUPPORT Trial: Multilevel Intervention to Improve Diverse Enrollment in Cancer Clinical Trials
NA Jonesboro, Arkansas +4 sites NCT06756607
This trial is looking for Black and Latino cancer patients who want to improve awareness and access to clinical trials. Participants will engage with resources and support to help connect them with research opportunities.
Recruiting
Burn Pit Exposure in Veterans: A Cancer Screening Pilot Study at the Inova Saville Cancer Screening & Prevention Center
NA Fairfax, Virginia NCT07485322
This trial is looking for veterans who have been exposed to burn pits to see if more frequent cancer screenings are beneficial. Participants will undergo intensive screenings over three years and will help researchers understand the impact of this approach on their health.
Recruiting
Occupational Cancer Screening in Firefighters: A Pilot Study Within the Inova Health System
NA Fairfax, Virginia NCT06931561
This trial is looking for firefighters aged 35 and older who have worked for at least 10 years. Participants will undergo whole-body MRI, ultrasound, and a cancer blood test to help understand cancer risks.
Recruiting
A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004)
PHASE3 Tucson, Arizona +4 sites NCT06136650
This trial is looking for men with metastatic castration-resistant prostate cancer who have been treated with one hormonal therapy before. Participants will receive either opevesostat with corticosteroids or other alternative treatments to see which is more effective.
Recruiting
A Study of Zolbetuximab Together With Pembrolizumab and Chemotherapy in Adults With Gastric Cancer
PHASE3 Birmingham, Alabama +4 sites NCT06901531
This trial is looking for adults with advanced stomach or gastroesophageal junction cancer. Participants will receive a combination of zolbetuximab, pembrolizumab, and chemotherapy, or a placebo with pembrolizumab and chemotherapy to see how well it works.
Recruiting
A Study of Xaluritamig Plus Abiraterone Versus Investigator's Choice in Participants With Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer
PHASE3 Goodyear, Arizona +4 sites NCT07213674
This trial is looking for men with specific advanced prostate cancer who have not received chemotherapy. Participants will receive a combination of two medications to see how well they work compared to other treatment options.
Recruiting
A Safety and Efficacy Study of EIK1001 in Combination With Pembrolizumab and Chemotherapy in Participants With Stage 4 Non-Small Cell Lung Cancer.
PHASE2 Daphne, Alabama +4 sites NCT07365319
This trial is looking for adults with stage 4 non-small cell lung cancer. Participants will receive a treatment combining EIK1001, pembrolizumab, and chemotherapy to assess safety and effectiveness.
Recruiting
Testing Whether Hormone Therapy With Ribociclib is as Effective as Chemotherapy Followed by Hormone Therapy With Ribociclib for the Treatment of High Anatomic Stage Breast Cancer With Low Recurrence Risk, The RxFINE-Low Trial
PHASE3 Jonesboro, Arkansas +4 sites NCT07391774
This trial is looking for women who are postmenopausal and have high stage breast cancer that is less likely to come back. Participants will compare hormone therapy and ribociclib to chemotherapy followed by hormone therapy and ribociclib.
Recruiting
A Study to Compare Setidegrasib (ASP3082) With Docetaxel, in People With Non-small Cell Lung Cancer With a KRAS G12D Mutation
PHASE3 Glendale, California +4 sites NCT07566052
This trial is looking for people with non-small cell lung cancer and a specific KRAS G12D gene mutation. Participants will receive either setidegrasib or docetaxel to see which one helps their cancer for a longer time.
Recruiting
Phase IIIb Study of Ribociclib + ET in Early Breast Cancer
PHASE3 Birmingham, Alabama +4 sites NCT05827081
This trial is looking for adults with early breast cancer that is hormone receptor positive and HER2 negative. If you join, you will receive ribociclib along with standard hormone therapy to see how effective this combination is.
Recruiting
Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer
PHASE3 Birmingham, Alabama +4 sites NCT06058377
This trial is looking for women with hormone receptor positive, HER2 negative stage II-III breast cancer. Participants will receive standard chemotherapy along with an immunotherapy drug called durvalumab to see if it helps prevent cancer from coming back.
Recruiting
A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.
PHASE3 Anchorage, Alaska +4 sites NCT07062965
This trial is looking for people with HR-positive, HER2-negative advanced breast cancer that has worsened after previous treatment. Participants will receive the study medicine PF-07248144 along with their normal treatment options to see how well they work together.
Recruiting
A Clinical Trial of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) to Treat Urothelial Cancer (MK-2870-031)
PHASE3 Washington D.C., District of Columbia +4 sites NCT07419295
This trial is looking for people with bladder cancer that has spread or got worse after previous treatments. Participants will receive a new treatment called sacituzumab tirumotecan and be compared to those receiving standard chemotherapy options.
Recruiting
A Clinical Trial of Adjuvant Intismeran (V940) With or Without Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) in High-Risk Stage I Non-Small Cell Lung Cancer (V940-014)
PHASE3 Sacramento, California +4 sites NCT07513376
This trial is looking for people with high-risk non-small cell lung cancer that has been surgically removed. Participants will receive either one or two investigational treatments to help prevent the cancer from coming back after surgery.
Recruiting
A Study to Access Intravenous (IV) Telisotuzumab Adizutecan in Combination With IV Bevacizumab Compared to Standard of Care IV Bevacizumabin Combination With Oral Trifluridine and Tipiracil in Adult Participants With Refractory Metastatic Colorectal Cancer
PHASE3 Goodyear, Arizona +4 sites NCT07525206
This trial is looking for adults with hard-to-treat metastatic colorectal cancer. Participants will receive either a new treatment involving telisotuzumab adizutecan combined with bevacizumab or the current standard treatment and will have regular medical check-ups during the study.
Recruiting

Where the Cancer studies are in Virginia

  • VCU Massey Comprehensive Cancer Center, Richmond70 trials
  • Virginia Cancer Specialists, Fairfax58 trials
  • University of Virginia Cancer Center, Charlottesville48 trials
  • VCU Massey Cancer Center at Stony Point, Richmond40 trials
  • NEXT Virginia, Fairfax37 trials
  • University of Virginia, Charlottesville34 trials

Counts are recruiting studies listing at least one site in Virginia, from ClinicalTrials.gov, refreshed every two days.

Cancer clinical trials in Virginia: common questions

How many Cancer clinical trials are recruiting in Virginia?
TrialFinder currently lists 580 recruiting Cancer clinical trials with study sites in Virginia. Results are updated regularly from ClinicalTrials.gov, the official U.S. registry of clinical studies.
Where are Cancer clinical trials located in Virginia?
Study sites for the Cancer trials listed on this page include Fairfax. Each trial page lists every participating site with contact details, so you can find the location closest to you.
Do I need insurance to join a Cancer clinical trial in Virginia?
No. Study-related care is covered by the trial sponsor at no cost to participants, including the study treatment, required lab tests and study visits. Many Cancer trials in Virginia also compensate participants for time and travel. Health insurance is not required to search or enroll.
How do I qualify for a Cancer clinical trial in Virginia?
Each study sets its own criteria based on age, Cancer diagnosis details, prior treatments, current medications and general health. The fastest way to find out is to contact a research site directly — most will pre-screen you by phone in 10 to 15 minutes at no charge. You can also create a free TrialFinder profile to be matched automatically.
Will I get a placebo instead of cancer treatment?
Almost never. Cancer trials compare a new treatment with the current standard treatment, or add the study drug to standard treatment. When a placebo is used it is on top of standard care, and the consent form states this before you decide.
Can I join a cancer trial if my cancer has spread?
Yes. Many recruiting cancer trials are written for advanced or metastatic disease, including people whose earlier treatments have stopped working. The listing states the stage and prior treatments it accepts.
Do I have to stop my current cancer treatment to join a trial?
It depends on the trial. Some enroll people whose current treatment has stopped working, some add the study drug to the treatment you are on, and some are for people who have not started treatment yet. Ask the study team before changing anything.
Are Clinical Trials Safe? What Patients Should Know
How clinical trial safety works — phases, IRB oversight, informed consent, and your right to withdraw — plus the real risks and questions to ask.
How to Know If You Qualify for a Clinical Trial
Every trial has eligibility criteria based on diagnosis, age, and medical history. Here's how to tell if you qualify — and what to do if you're not sure.
Clinical Trials Without Insurance: What You Need to Know
Clinical trials cover the cost of study-related care, making them one of the few ways to access treatment without health insurance. Here's what's covered.
All guides →

Check Your Eligibility

Create a free profile and our AI will match you to Cancer trials near you in Virginia.

Get Matched — Free
No insurance required

Breast cancer trials test new chemotherapy regimens, immunotherapy combinations, targeted therapies, and early-detection methods across all stages of breast cancer.

All Cancer trials →